Merat Shahin, Aduli Mohsen, Kazemi Rozana, Sotoudeh Masoud, Sedighi Nahid, Sohrabi Masoud, Malekzadeh Reza
Digestive Disease Research Center, Shariati Hospital, Medical Sciences/University of Tehran, Tehran, Iran.
Dig Dis Sci. 2008 Aug;53(8):2246-50. doi: 10.1007/s10620-007-0109-6. Epub 2007 Nov 30.
Probucol, a lipid-lowering agent with antioxidant effects, is effective in normalizing liver enzymes in patients with nonalcoholic steatohepatitis (NASH). We studied changes in the liver histology of patients with NASH after use of probucol for one year.
Ten patients with biopsy-proven NASH were included. Subjects were given 500 mg probucol daily. Liver biopsies were performed before treatment and after one year.
Eight patients completed treatment. The mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels decreased from 94 and 55 to 41 and 26, respectively (P = 0.004 and 0.001 respectively). The scores for hepatic steatosis and necroinflammation decreased from 7.4 to 5.6 (P = 0.03). The fibrosis score changed from 1.1 to 1.3 (P = 0.79). No adverse drug effects were observed.
Probucol is effective in normalizing aminotransferase levels in patients with NASH. It also significantly reduces the histology grade of steatohepatitis after one year of treatment.
普罗布考是一种具有抗氧化作用的降脂药物，对非酒精性脂肪性肝炎（NASH）患者的肝酶正常化有效。我们研究了普罗布考治疗一年后NASH患者肝脏组织学的变化。
纳入10例经活检证实为NASH的患者。受试者每天服用500毫克普罗布考。在治疗前和治疗一年后进行肝脏活检。
8例患者完成治疗。平均丙氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）水平分别从94和55降至41和26（P分别为0.004和0.001）。肝脂肪变性和坏死性炎症评分从7.4降至5.6（P = 0.03）。纤维化评分从1.1变为1.3（P = 0.79）。未观察到药物不良反应。
普罗布考对NASH患者的氨基转移酶水平正常化有效。治疗一年后，它还能显著降低脂肪性肝炎的组织学分级。
